Amyris, Inc. announced that Aprinnova—its joint venture with Nikkol Group—launched pharmaceutical grade Neossance Squalane USP (INCI: Squalane), which is derived from sugarcane.
Previously, the market used shark-derived squalane as it was the only source reference in the regulatory monograph for squalane. This new material meets industry standards set by the United States Pharmacopeia (USP) and the National Formulary (NF) for drug actives and pharmaceutical excipients, which ensure product quality, purity and consistency.
Since Amyris announced its Aprinnova cosmetic ingredients collaboration in March 2017, annual revenue grew more than 50%. Various product applications such as dermal cosmetics and therapeutic skin creams and ointments can now be expanded upon with USP/NF approval.
“We are very pleased to have met the USP and NF requirements, which showcases our adherence to a philosophy of manufacturing and distributing the highest performance, sustainable products through a best-in-class production process,” said Caroline Hadfield, senior vice president, personal care, Amyris.
“We are delighted to provide a sustainable and naturally sourced squalane to this important new market for Aprinnova, while providing our customers and their end market customers with non-animal, cruelty-free high-performance ingredients for a growing variety of products.”
